ARWR Stock - Arrowhead Pharmaceuticals, Inc.
Unlock GoAI Insights for ARWR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $829.45M | $3.55M | $240.74M | $243.23M | $138.29M |
| Gross Profit | N/A | $3.55M | $240.74M | $243.23M | $138.29M |
| Gross Margin | 0.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $98.35M | $-601,080,000 | $-205,002,000 | $-178,507,000 | $-149,036,000 |
| Net Income | $-1,631,000 | $-599,493,000 | $-205,275,000 | $-176,063,000 | $-140,848,000 |
| Net Margin | -0.2% | -16882.4% | -85.3% | -72.4% | -101.9% |
| EPS | $-0.01 | $-5.00 | $-1.91 | $-1.67 | $-1.36 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 5th 2024 | Goldman | Initiation | Neutral | $31 |
| December 4th 2023 | BofA Securities | Initiation | Buy | $29 |
| September 19th 2023 | Citigroup | Initiation | Neutral | $33 |
| July 21st 2023 | TD Cowen | Initiation | Outperform | - |
| May 12th 2023 | SVB Securities | Downgrade | Market Perform | $40 |
| April 26th 2023 | SMBC Nikko | Initiation | Outperform | $80 |
| April 12th 2023 | SVB Securities | Upgrade | Outperform | $35← $21 |
| March 21st 2023 | Bernstein | Initiation | Market Perform | $27 |
| September 9th 2022 | Morgan Stanley | Initiation | Equal Weight | $41 |
| May 11th 2022 | Robert W. Baird | Upgrade | Outperform | $60← $71 |
Earnings History & Surprises
ARWREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 9, 2026 | $0.80 | — | — | — |
Q4 2025 | Nov 25, 2025 | $-0.11 | $-0.18 | -61.3% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.94 | $-1.26 | -34.0% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.06 | $2.75 | +4683.3% | ✓ BEAT |
Q1 2025 | Feb 10, 2025 | $-0.42 | $-1.39 | -231.0% | ✗ MISS |
Q4 2024 | Nov 26, 2024 | $-1.05 | $-1.38 | -31.4% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.58 | $-1.38 | -137.9% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.06 | $-1.02 | -1600.0% | ✗ MISS |
Q1 2024 | Feb 6, 2024 | $-0.78 | $-1.24 | -59.0% | ✗ MISS |
Q4 2023 | Nov 29, 2023 | $-0.70 | $-1.03 | -47.1% | ✗ MISS |
Q3 2023 | Aug 7, 2023 | $-0.58 | $-0.96 | -65.5% | ✗ MISS |
Q2 2023 | May 2, 2023 | $-0.64 | $0.45 | +170.3% | ✓ BEAT |
Q1 2023 | Feb 6, 2023 | $1.14 | $-0.39 | -134.2% | ✗ MISS |
Q4 2022 | Nov 28, 2022 | $-0.57 | $-0.81 | -42.1% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.45 | $-0.68 | -51.1% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.08 | $0.41 | +612.5% | ✓ BEAT |
Q1 2022 | Feb 2, 2022 | $-0.22 | $-0.60 | -172.7% | ✗ MISS |
Q4 2021 | Nov 22, 2021 | $-0.11 | $-0.61 | -478.5% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.08 | $-0.29 | -262.5% | ✗ MISS |
Latest News
Piper Sandler Maintains Overweight on Arrowhead Pharma, Raises Price Target to $100
📈 PositiveRBC Capital Maintains Outperform on Arrowhead Pharma, Raises Price Target to $80
📈 PositiveB of A Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $81
📈 PositiveArrowhead Pharmaceuticals shares are trading higher after the company announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT
📈 PositiveArrowhead Doses First Subjects In Phase 1/2a Clinical Trial Of ARO-MAPT, Investigational RNAi Therapeutic Developed As Treatment For Tauopathies Including Alzheimer's Disease
📈 PositiveArrowhead Pharmaceuticals shares are trading higher. Yesterday, the company announced the FDA granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia.
📈 PositiveArrowhead Pharmaceuticals Gets FDA's Breakthrough Designation For Plozasiran As Adjunct To Diet To Lower Triglyceride Levels In Adults With Severe Hypertriglyceridemia
📈 PositiveHC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $85
📈 PositiveB of A Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $62
📈 PositiveChardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
📈 PositiveArrowhead Pharmaceuticals shares are trading higher after the company repeorted better-than-expected Q4 financial results.
📈 PositiveMorgan Stanley Maintains Equal-Weight on Arrowhead Pharma, Raises Price Target to $48
➖ NeutralCORRECTION: Arrowhead Pharma Q4 EPS $(0.18) Beats $(0.29) Estimate, Sales $256.472M Beat $175.862M Estimate
📈 PositiveArrowhead Pharma Q4 EPS $(0.09) Beats $(0.29) Estimate, Sales $256.478M Beat $175.862M Estimate
📈 PositiveArrowhead Pharmaceuticals FY25 EPS $(0.01) Up From $(5.00) YoY; Revenue $829.448M Up From $3.551M YoY
📈 PositiveArrowhead Pharmaceuticals Earns $200M Milestone Payment From Sarepta Therapeutics
📈 PositiveGoldman Sachs Maintains Neutral on Arrowhead Pharma, Raises Price Target to $48
➖ NeutralRBC Capital Maintains Outperform on Arrowhead Pharma, Raises Price Target to $52
📈 PositiveChardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
📈 PositivePiper Sandler Maintains Overweight on Arrowhead Pharma, Raises Price Target to $70
📈 PositiveFrequently Asked Questions about ARWR
What is ARWR's current stock price?
What is the analyst price target for ARWR?
What sector is Arrowhead Pharmaceuticals, Inc. in?
What is ARWR's market cap?
Does ARWR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ARWR for comparison